AURA
NASDAQ HealthcareAura Biosciences, Inc. - Common Stock
Biotechnology
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
�� 市场数据
| 价格 | $7.29 |
|---|---|
| 成交量 | 427,553 |
| 市值 | 467.66M |
| 贝塔系数 | 0.350 |
| RSI（14日） | 81.1 超买 |
| 200日均线 | $6.12 |
| 50日均线 | $6.17 |
| 52周最高 | $7.48 |
| 52周最低 | $4.34 |
| Forward P/E | -3.59 |
| Price / Book | 3.39 |
🎯 投资策略评分
AURA 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (75/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (10/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 AURA in your text
粘贴任何文章、记录或帖子 — 工具将提取 AURA 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.